Roivant, Pfizer shares rise as Roche agrees to buy immunology company for $7.1 billionMarket Watch • 10/23/23
Roche Enters Into a Definitive Agreement to Acquire Telavant Including Rights to Novel TL1A Directed Antibody (RVT-3101) for the Treatment of Inflammatory Bowel Disease From RoivantGlobeNewsWire • 10/23/23
Roivant Sciences Ltd. (ROIV) Moves 21.6% Higher: Will This Strength Last?Zacks Investment Research • 09/27/23
Roivant stock could go higher on monetization potential of ‘blockbuster' assetsProactive Investors • 09/26/23
Immunovant and Roivant jump as new drug shapes up to become blockbusterProactive Investors • 09/26/23
Roivant Announces Positive Initial IMVT-1402 Phase 1 SAD and 300 mg Subcutaneous MAD ResultsGlobeNewsWire • 09/26/23
Roivant Announces Redemption Fair Market Value in Connection with Redemption of its Outstanding WarrantsGlobeNewsWire • 08/17/23
Roivant Sciences earnings come in below Street estimates despite VTAMA sales growthProactive Investors • 08/14/23
Top Biotech Roivant, Formed By Vivek Ramaswamy, Reports Steep Losses, Light SalesInvestors Business Daily • 08/14/23
Roivant Reports Financial Results for the First Quarter Ended June 30, 2023, and Provides Business UpdateGlobeNewsWire • 08/14/23
11 Revived Stocks That Traded For $5 Or Less Are Now Worth BillionsInvestors Business Daily • 08/04/23